Marizyme Past Earnings Performance
Past criteria checks 0/6
Marizyme's earnings have been declining at an average annual rate of -62.5%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 44.4% per year.
Key information
-62.5%
Earnings growth rate
-51.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 44.4% |
| Return on equity | n/a |
| Net Margin | -14,389.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Marizyme makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -53 | 14 | 2 |
| 31 Mar 24 | 1 | -69 | 17 | 2 |
| 31 Dec 23 | 1 | -65 | 17 | 2 |
| 30 Sep 23 | 1 | -79 | 11 | 2 |
| 30 Jun 23 | 0 | -48 | 8 | 3 |
| 31 Mar 23 | 0 | -35 | 7 | 3 |
| 31 Dec 22 | 0 | -38 | 8 | 4 |
| 30 Sep 22 | 0 | -20 | 9 | 4 |
| 30 Jun 22 | 0 | -20 | 9 | 4 |
| 31 Mar 22 | 0 | -14 | 8 | 3 |
| 31 Dec 21 | 0 | -11 | 7 | 2 |
| 30 Sep 21 | 0 | -8 | 7 | 2 |
| 30 Jun 21 | 0 | -9 | 8 | 1 |
| 31 Mar 21 | 0 | -8 | 6 | 1 |
| 31 Dec 20 | 0 | -6 | 5 | 1 |
| 30 Sep 20 | 0 | -3 | 3 | 0 |
| 30 Jun 20 | 0 | -2 | 2 | 0 |
| 31 Mar 20 | 0 | -1 | 1 | 0 |
| 31 Dec 19 | 0 | -1 | 1 | 0 |
| 30 Sep 19 | 0 | -1 | 1 | 0 |
| 30 Jun 19 | 0 | 0 | 0 | 0 |
| 31 Mar 19 | 0 | 0 | 0 | 0 |
| 31 Dec 18 | 0 | 0 | 0 | 0 |
| 30 Sep 18 | 0 | -1 | 0 | 0 |
| 30 Jun 18 | 0 | -1 | 0 | 0 |
| 31 Mar 18 | 0 | -1 | 0 | 0 |
| 31 Dec 17 | 0 | -1 | 0 | 0 |
| 31 Dec 16 | 0 | -1 | 0 | 0 |
| 31 Dec 15 | 0 | -9 | 1 | 0 |
| 31 Dec 14 | 0 | -10 | 1 | 0 |
Quality Earnings: MRZM is currently unprofitable.
Growing Profit Margin: MRZM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MRZM is unprofitable, and losses have increased over the past 5 years at a rate of 62.5% per year.
Accelerating Growth: Unable to compare MRZM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MRZM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: MRZM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.